title: LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment.
abstract: Psoriasis is an immune-mediated highly heterogeneous skin disease in which genetic as well as environmental factors play important roles. In spite of the local manifestations of the disease, psoriasis may progress to affect organs deeper than the skin. These effects are documented by epidemiological studies, but they are not yet mechanistically understood. In order to provide insight into the systemic effects of psoriasis, we performed a nontargeted high-resolution LC-MS metabolomics analysis to measure plasma metabolites from individuals with mild or severe psoriasis as well as healthy controls. Additionally, the effects of the anti-TNFα drug Etanercept on metabolic profiles were investigated in patients with severe psoriasis. Our analyses identified significant psoriasis-associated perturbations in three metabolic pathways: (1) arginine and proline, (2) glycine, serine and threonine, and (3) alanine, aspartate, and glutamate. Etanercept treatment reversed the majority of psoriasis-associated trends in circulating metabolites, shifting the metabolic phenotypes of severe psoriasis toward that of healthy controls. Circulating metabolite levels pre- and post-Etanercept treatment correlated with psoriasis area and severity index (PASI) clinical scoring (R(2) = 0.80; p < 0.0001). Although the responsible mechanism(s) are unclear, these results suggest that psoriasis severity-associated metabolic perturbations may stem from increased demand for collagen synthesis and keratinocyte hyperproliferation or potentially the incidence of cachexia. Data suggest that levels of circulating amino acids are useful for monitoring both the severity of disease as well as therapeutic response to anti-TNFα treatment.
authors.affiliation: Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry 2, Karolinska Institutet , SE-17177 Stockholm, Sweden.
authors.forename: Muhammad Anas
authors.initials: MA
authors.lastname: Kamleh
authors.forename: Stuart G
authors.initials: SG
authors.lastname: Snowden
authors.forename: Dmitry
authors.initials: D
authors.lastname: Grapov
authors.forename: Gavin J
authors.initials: GJ
authors.lastname: Blackburn
authors.forename: David G
authors.initials: DG
authors.lastname: Watson
authors.forename: Ning
authors.initials: N
authors.lastname: Xu
authors.forename: Mona
authors.initials: M
authors.lastname: Ståhle
authors.forename: Craig E
authors.initials: CE
authors.lastname: Wheelock
mesh_terms: D000596:Amino Acids / Q000097:blood* / Q000187:drug effects; D002853:Chromatography, Liquid / Q000379:methods; D015331:Cohort Studies; D000068800:Etanercept / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D055432:Metabolomics / Q000379:methods*; D015999:Multivariate Analysis; D011565:Psoriasis / Q000235:genetics / Q000378:metabolism*; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000596:Amino Acids; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept
keywords: Etanercept; HILIC; Mass spectrometry; collagen; diabetes; keratinocyte; metabolomics; pathway enrichment; psoriasis